Blog
Key Takeaways from the 2025 ixlayer Client Advisory Meeting
In Case You Missed It: Key Takeaways from the 2025 ixlayer Client Advisory Meeting In early March, ixlayer hosted an
April 29, 2025
ixlayer’s unified direct-to-patient platform, helps biopharma transform the patient experience
Simplify and Accelerate the Connection to Care
Scheduled a visit with a
physician after receiving
abnormal lab results.
Patient activation increase
vs. traditional outreach.
Increase in diagnostic testing compliance vs. U.S benchmark.
Intuitive interface and simple one-time sign-on supports continuous patient engagement
Connection to PCPs and Specialists virtually and in-person accelerates the connection to care
Deep partnerships across the healthcare ecosystem support multiple, differentiated patient journeys
Proactive care and convenient health access drive earlier interventions and help patients achieve their health goals
ixlayer connects a vast health ecosystem for a convenient and seamless virtual patient experience. Users can screen for health conditions, easily monitor their health, seamlessly connect with care providers and have medication delivered all without leaving our platform.
Seamlessly integrate with a vast health ecosystem and launch services to support specific brand initiatives.
Built on a secure technological backbone, our flexible product design enables rapid deployment and scalability, and allows us to configure solutions to best meet our clients’ needs across multiple therapeutic areas.
Telehealth services, lab testing, Rx fulfillment, benefits verification, and more can be implemented across a patient journey designed to support different patient needs and priorities.
We offer our clients the opportunity to deliver a personalized healthcare journey to all patients with our fully integrated, configurable platform. We have powered over 1,100 nationwide programs and enabled over 4 million patient care journeys for greater operational efficiency, patient access, and improved outcomes.
Across the biopharma industry,
our clients value our speed, our service and our solutions.
The latest research, news and expert opinion keeping you up to date on DTP industry innovation.
ixEngage removes barriers to care by accelerating pre-treatment and routine CBC tests used for hundreds of conditions, including asthma, heart
We surveyed a group of pharmaceutical marketing executives, and over 50% are exploring or preparing a direct-to-patient (DTP) platform, á
‘ixEngage’ simplifies and accelerates the connection to care SAN FRANCISCO – September 11, 2024 – ixlayer, a healthcare technology platform
Direct-to-patient platforms, including telehealth, digital HCP connection, and multimodal diagnostic testing, have improved accessibility and convenience on their march to
A new ixlayer survey shows a growing consensus on the transformative potential of at-home diagnostic testing to revolutionize healthcare accessibility,
This article was originally published by Fierce Pharma. Physicians don’t mind patients choosing at-home testing options over coming in for
In Case You Missed It: Key Takeaways from the 2025 ixlayer Client Advisory Meeting In early March, ixlayer hosted an
Pharma’s Role in Improving the Health Experience: Understanding Patient Expectations Patients have become accustomed to digital health, but they struggle
ixlayer and Ipsos’ “ixInsights 2025” Study Reveals Consumer Expectations for Digital Health and Pharma’s Role in Enhancing Patient Experience Study
IX Layer Inc.
447 Sutter Street, Suite 405, PMB 53
San Francisco, CA 94108
IX Layer Inc.
222 Broadway, 22nd Floor
New York, NY 10038